|
Vascarta and CUNY Report Preclinical Breakthrough in Glioblastoma Treatment
|
Oncology |
Press Release |
2025 |
|
67th ASH Meeting - Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts The Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
|
Sickle Cell Disease |
Poster Presentation |
2025 |
|
Cells - Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions
|
Oncology |
Published Manuscript |
2025 |
|
Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis
|
Osteoarthritis |
Press Release |
2025 |
Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team
|
Public Relations |
Press Release |
2025 |
|
National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2025 |
|
Summary of Vascarta Patent Portfolio
|
Sickle Cell Disease |
Press Release |
2025 |
|
Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2025 |
|
The Scientific Origins Behind Vascarta Inc. and VAS-101 (Vasceptor®)
|
Sickle Cell Disease |
Promotional |
2025 |
|
Vascarta Commences Proof of Concept Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease in the United States
|
Sickle Cell Disease |
Press Release |
2025 |
|
Chatham & Short Hills Magazine
|
Public Relations |
Magazine |
2025 |
|
Vascarta commences a Phase I clinical Study of VAS101 in Osteoarthritis
|
Osteoarthritis |
Press Release |
2025 |
|
Patented Transdermal Drug Candidate from Vascarta May Offer a Convenient & Cost-Effective Way to Treat Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2025 |
|
Geroscience – Salutary Effects of Transdermal Curcumin on Multiple Indices of Health Span in Rodent Models of Normal Aging and Lifespan
|
Aging |
Published Manuscript |
2025 |
|
PNAS Nexus – Targeting Sickle Cell Pathobiology With Novel Transdermal Curcumin
|
Sickle Cell Disease |
Published Manuscript |
2025 |
|
Vascarta and CUNY Collaborate to Improve Chemotherapy Efficacy and Safety
|
Oncology |
Research Collaboration Agreement |
2025 |
|
VAS-101 Enhances Red Blood Cell Preservation
|
Red Blood Cell Health |
Press Release |
2025 |
|
Vascarta Promotional Video
|
Public Relations |
Video |
2024 |
|
Scientific Reports – Biopreservation and Reversal of Oxidative Injury During Blood Storage by a Novel Curcumin-based Gel Formulation
|
Red Blood Cell Health |
Published Manuscript |
2024 |
|
66th ASH Meeting – Mechanism Based Treatable Targets for Organ Damage and Pain in SCD
|
Sickle Cell Disease |
Poster Presentation |
2024 |
|
Vascarta Presents Breakthrough Sickle Cell Treatment at ASH Conference
|
Sickle Cell Disease |
Press Release |
2024 |
|
Joel Friedman - Vascarta Article, Einstein Magazine, Winter-Spring
|
Public Relations |
Magazine Article |
2023 |
|
Promising Data for Transdermal Curcumin in Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2023 |
|
Novel Transdermal Curcumin Therapeutic Preserves Endothelial Barrier Function in a High-Dose LPS Rat Mdel; Artifitial Cells, Nanomedicine, and Biotechnology
|
Endothelial Dysfunction |
Published Manuscript |
2023 |
|
Published poster: Mechanism-based Targeting of Sickle Cell Pathobiology and Pain with Novel Transdermal Curcumin
|
Sickle Cell Disease |
Poster Presentation |
2023 |
|
65th ASH Meeting – Mechanism Based Treatable Targets for Organ Damage and Pain In SCD
|
Sickle Cell Disease |
Poster Presentation |
2023 |
